Frederique Menzaghi Ph.D., Chief Scientific Officer, SVP-R&D at Cara Therapeutics, Inc. (CARA), sold 2,733 shares at $4.91 ($13K) on 2023-04-04, disclosed to the SEC on 2023-04-06.
Scheduled sale ($13k) by Chief Scientific Officer, SVP-R&D under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| CARA | SELL | 2022-12-23 | $40K | — | Filing → |
| CARA | SELL | 2022-04-05 | $21K | — | Filing → |
| CARA | SELL | 2022-03-01 | $22K | — | Filing → |